본문 바로가기
KERD
논문KCI 등재

통합 의학 치료로 5년 생존 및 완전 관해에 도달한 췌장암 증례 보고 1례

Case Report on the Five-year Survival and Complete Response of a Patient with Pancreatic Cancer Treated with Integrative Medicine

방선휘|정범진|김지수|박경덕|오유나|정유진
대한한방내과학회 (The Society Of Korean Oriental Internal Medicine)|2023.06|대한한방내과학회지 (The Journal of Korean Oriental Internal Medicine)|제44권 제3호|pp. 562-577

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

Traditional Korean MedicinePancreas cancerIntegrative Medicine TreatmentComplete Response
주제분류한의학

초록

Objectives: This is a five-year survival and complete response (CR) report on pancreatic cancer treated with western medicine and Korean traditional medicine. Method: A 59-year-old woman diagnosed with pancreatic cancer visited ⃝⃝ Korean traditional medicine hospital after neoadjuvant chemotherapy and pylorus-preserving pancreaticoduodenectomy. She was treated with Korean traditional medicine, including acupuncture, abdominal moxibustion, wild ginseng pharmacopuncture, and herbal medicine, which was based on integrated medicine therapy (IMT), from March 2018 to September 2022. The tumor size was measured by scanning with computed tomography (CT), magnetic resonance imaging, and positron-emission tomography/CT. Adverse events were evaluated using laboratory conclusion and National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Result: During four years and three months of treatment, IMT maintained safety. The patient finally reached five-year survival without any recurrence or complication (CR) on October 26, 2022. Conclusion: We suggest that an integrative approach including Korean traditional medicine can be a meaningful treatment option for pancreatic cancer. Further studies should be performed to establish the proper treatment protocol of integrative medicine for pancreatic cancer.

Abstract

Objectives: This is a five-year survival and complete response (CR) report on pancreatic cancer treated with western medicine and Korean traditional medicine. Method: A 59-year-old woman diagnosed with pancreatic cancer visited ⃝⃝ Korean traditional medicine hospital after neoadjuvant chemotherapy and pylorus-preserving pancreaticoduodenectomy. She was treated with Korean traditional medicine, including acupuncture, abdominal moxibustion, wild ginseng pharmacopuncture, and herbal medicine, which was based on integrated medicine therapy (IMT), from March 2018 to September 2022. The tumor size was measured by scanning with computed tomography (CT), magnetic resonance imaging, and positron-emission tomography/CT. Adverse events were evaluated using laboratory conclusion and National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Result: During four years and three months of treatment, IMT maintained safety. The patient finally reached five-year survival without any recurrence or complication (CR) on October 26, 2022. Conclusion: We suggest that an integrative approach including Korean traditional medicine can be a meaningful treatment option for pancreatic cancer. Further studies should be performed to establish the proper treatment protocol of integrative medicine for pancreatic cancer.

참고문헌 (37)

  1. Siegel R, "Cancer statistics, 2012", CA Cancer J Clin, 62(1), pp.10~29 (2012)
  2. Siegel R, "Cancer statistics, 2020", CA Cancer J Clin, 70(1), pp.7~30 (2020)
  3. "Plymouth Meeting"[URL]
  4. 방승민, "췌장암의 감시와 조기 진단", 대한췌담도학회지, 20(1), pp.1~4 (2015), 대한췌장담도학회[DOI]
  5. 김재우, "췌장암의 최신치료", 대한내과학회지, 77(6), pp.695~702 (2009), 대한내과학회
  6. 류지곤, "절제 불가능한 췌장암 항암치료의 최신 지견", 대한소화기학회지, 66(3), pp.150~153 (2015), 대한소화기학회
  7. Park JG, "Oncology", pp.317~318 (2012), Iljogak
  8. 한가진, "췌장암에 대한 국내 한의학 연구 동향 고찰 - 국내 한의학 논문을 중심으로 -", 대한한방내과학회지, 40(1), pp.70~88 (2019), 대한한방내과학회[DOI]
  9. Schmitz H, "American College of Sports Medicine roundtable on exercise guidelines for cancer survivors", Med Sci Sports Exerc, 42(7), pp.1409~1426 (2010)
  10. Shapiro CL, "Ovarian failure after adjuvant chemotherapy isassociated with rapid bone loss in women with early-stage breast cancer", J Clin Oncol, 19(14), pp.3306~3310 (2001)
  11. Li M, "Different Survival Benefits of Chinese Medicine for Pancreatic Cancer : How to Choose", Chin J Integr Med, 24(3), pp.178~184 (2018)
  12. 고은주, "췌장암 간전이 환자의 통합 암 치료에 대한 증례보고", 대한암한의학회지, 26(1), pp.39~48 (2021), 대한암한의학회
  13. Eisenhauer EA, "New response evaluation criteria in solid tumours: Revised RECIST guideline(version1.1)", Eur J Cancer, 45(2), pp.228~247 (2009)
  14. 고은비, "항암화학요법과 통합의학치료를 병행하여 부분 관해 된 간전이 동반 말기 췌장암 1례", 대한한방내과학회지, 41(2), pp.166~176 (2020), 대한한방내과학회[DOI]
  15. Sharma S, "Tumor markers in clinical practice:General principle sand guidelines", Indian journal of medical and paediatric oncology. official journal of Indian Society of Medical & Paediatric Oncology, 30(1), pp.1~8 (2009)
  16. Annual report of Korean Central Cancer Registry (2017), "Korean Central Cancer Registry", ~ (2020)
  17. 이광식, "Economic Burden of Cancer in Korea during 2000-2010", Cancer Research and Treatment, 47(3), pp.387~398 (2015), 대한암학회[DOI]
  18. Isaji S, "International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017", Pancreatology, 18(1), pp.2~11 (2018)
  19. National Comprehensive Cancer Network, "pancreatic adenocarcinoma, version 1. 2020, NCCN clinical practice guidelines in oncology", ~ (2020)
  20. Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches, "Korean Clinical Practice Guideline Development Committee", 10~ (2021)
  21. Burris HA 3rd, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial", J Clin Oncol, 15(6), pp.2403~2413 (1997)
  22. Mizrahi JD, "Pancreatic cancer", Lancet, 395(10242), pp.2008~2020 (2020)
  23. Leonhardt CS, "Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma", J Pancreatol, 3, pp.1~11 (2020)
  24. Catenacci DV, "Randomized phase Ib", II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer, 2015, pp.33(36), 4284~4292
  25. Conroy T, "Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364(19), pp.1817~1825 (2011)
  26. Kim JM, "Case Report of the Pancreatic Cancer Patient after Pancreatoduodenectomy who is Taking the HangAm-Plus to Anti-metastasis and Preventing Recurrence", J of Kor Traditional Oncology, 16(1), pp.33~39 (2011)
  27. 김재욱, "재발된 췌장암 환자의 한의 기반 통합 암 치료에 대한 증례보고", 대한암한의학회지, 27(1), pp.1~12 (2022), 대한암한의학회
  28. extract therapy in patients with locally advanced or metastatic pancreatic cancer: A randomised clinical trial on overall survival, "European Journal of Cancer", 2013, 3788~3797
  29. Rasi G, "Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats", International Jounal of Cancer, 57(5), pp.701~705 (1994)
  30. Townsend DM, "The role of glutathione-S-transferase in anti-cancer drug resistance", Oncogene, 22(47), pp.7369~7375 (2003)
  31. Fritz H, "Intravenous Vitamin C and Cancer : A Systematic Review", Integr Cancer Ther, 13(4), pp.280~300 (2014)
  32. Yuhan X, "Adjuvant treatment for triple-negative breast cancer : a retrospective study of immunotheraphy with autologous cytokine-induced killer cells in 294 patients", Cancer Biol Med, 16(2), pp.350~360 (2019)
  33. 박수정, "췌장암 한의 임상진료지침 개발 예비 연구", 대한암한의학회지, 22(1), pp.1~11 (2017), 대한암한의학회[DOI]
  34. 오소미, "국내 십전대보탕 최근 연구 동향 분석", 대한예방한의학회지, 18(1), pp.113~123 (2014), 대한예방한의학회
  35. Lee SY, "Effects of Samculkunbitang of the Immunosuppression Induced by Methrotrexate in Rats", The Journal of Pediatrics of Korean Medicine, 12(1), pp.257~276 (1998)
  36. Joo EJ, "Novel roles of ginsenoside Rg3 in apoptosis through downregulation of epidermal growth factor receptor", Chem Biol Interact, 233, pp.25~34 (2015)
  37. Elluru S, "Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador", Arzneimittelforschung, 56(6), pp.461~466 (2006)

관련 논문AI추천

통합암치료를 적용한 폐전이 동반 췌장암 환자의 장기간 추적관찰 증례보고김지수, 박경덕, 방선휘, 오유나, 정범진, 정유진대한한방내과학회 · 대한한방내과학회지2023 · 제44권 제4호항암화학요법과 통합의학치료를 병행하여 부분 관해 된 간전이 동반 말기 췌장암 1례고은비, 송미화, 신광순, 장권준, 장주영대한한방내과학회 · 대한한방내과학회지2020 · 제41권 제2호수술 및 항암 방사선 표준 치료 이후의 한양방 통합치료를 통해 5년 무병생존에 도달한 3기 직장암 환자 1례에 대한 보고김지수, 박경덕, 방선휘, 오유나, 정범진, 정유진대한한방내과학회 · 대한한방내과학회지2023 · 제44권 제3호췌장암에 대한 국내 한의학 연구 동향 고찰 - 국내 한의학 논문을 중심으로 -성신, 김성수, 박은주, 이아름, 이준명, 정하영, 한가진대한한방내과학회 · 대한한방내과학회지2019 · 제40권 제1호한의기반 통합암치료를 통한 재발성 담낭암 환자의 증상 호전 증례보고고은주, 도성국, 박지혜, 송시연, 유화승, 이연월대한한방내과학회 · 대한한방내과학회지2022 · 제43권 제3호재발된 자궁경부암 환자의 한의 기반 통합 암 치료에 대한 증례보고박소정, 박지혜, 송시연, 유화승, 조영민, 주한음대한한방내과학회 · 대한한방내과학회지2022 · 제43권 제4호

이 간행물의 다른 논문 (20건)

Yukgunja-tang for Irritable Bowel Syndrome: A Protocol for a Systematic Review and Meta-Analysis박재우, 고석재, 김민정, 박채현, 조민석, 이강욱pp. 285-293Ovalbumin으로 유발된 천식 동물모델에서 GGX의 효과김태현, 우성천, 김승형, 양원경, 이수원, 박양춘pp. 294-312심부전의 한약 임상연구에 활용된 한약재에 대한 기구축 DB(K-HERB NETWORK)를 활용한 네트워크 분석박수빈, 배기상, 김예지, 김철현, 윤인애, 추홍민, 임정태pp. 313-353제2형 당뇨병 환자에서 혈당강하제와 보중익기탕 병용 투여가 혈당 변화에 미치는 영향 및 안전성 연구송미령, 노지원, 안영민, 안세영, 이병철, 정우녕, 오승현pp. 354-365특발성 폐섬유증의 통합의료 협진 모델 개발을 위한 의료진 및 환자 대상 설문조사 연구최혜숙, 이범준, 신정원, 정희재, 진수현, 김관일, 양정민, 김수덕, 박지원pp. 366-386
원문 보기